Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4075 - Delayed initiation of HER2-targeted therapy (HER2Tx) is associated with a higher risk of relapse for early stage (ES) HER2-positive (HER2+) breast cancer (BrCa)


10 Oct 2016


Poster display


Giuseppe Gullo


Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364


G. Gullo1, R. Bose2, N. Walsh3, M. Maltese1, D. Fennelly4, J. Walshe4, J. Ballot5, J. Crown4

Author affiliations

  • 1 Medical Oncology, St Vincents University Hospital, 4 - Dublin/IE
  • 2 Medical Oncology, St Vincents University Hospital, Dublin/IE
  • 3 National Institute For Cellular Biotechnology, Dublin City University, Dublin/IE
  • 4 Medical Oncology, St Vincents University Hospital, N/A - Dublin/IE
  • 5 Medical Oncology, Cancer Clinical Research Trust, N/A - Dublin/IE


Abstract 4075


The prognosis of HER2+ ESBrCa has improved since the addition of trastuzumab (H) to chemotherapy (CRx). Several H/CRx regimens have been validated in random assignment trials. Some include delayed H, either at the completion of CRx (as per HERA) or, with taxanes (T) after cycles of non-H containing CRx with anthracycline (A) and cyclophosphamide (C) (e.g. AC-TH). Conversely, in the BCIRG TCH program (C = carboplatin), H is administered from day 1.


We conducted a retrospective analysis of our database of all pts with HER2+ ESBrCa (stages I-III) who received H. The date of first biopsy (Bx) was recorded as the initial diagnosis (Dx). The primary endpoint was relapse-free survival (RFS), i.e. time from start of H to the date of relapse.


We identified 592 pts treated between September 2001 and March 2013 and performed outcome analyses on 452 pts with a minimum of 36 months of follow up (FU). Pts characteristics: Neoadjuvant (NeoA) 95/Adjuvant (Adj) 357, N+ 233 (52%)/N-211 (47%)/unknown = 8 (1%), ER+ 282 (62%)/ER- 167 (37%)/unknown 3. Therapy administered: TCH 251 (56%)/AC-TH 84 (19%)/ other taxane-based + H 37 (8%)/sequential H 13 (3%)/single-agent H/unknown 18 (4%). Median FU is 70.1 months (range 5.5-169.6). The median time from BrCa Dx to first H is 11.9 weeks. Overall RFS rate is 90.5%. The relative risk of relapse for pts starting H > 12 weeks from Dx is significantly increased with an HR 2.55 (95%CI 1.3-4.98 p = 0.006). This effect is particularly evident in pts with ER negative (p = 0.0069), node positive (p = 0.0197), and age


These data suggest the possibility that the timing of initiation of H may be a determinant of outcome. Delay beyond 12 weeks increased the risk of relapse. Intriguingly, the very early administration of H, i.e. pre-operatively completely eliminated the negative prognostic effects of age and nodal status.

Clinical trial identification

Not applicable.

Legal entity responsible for the study

Medical Oncology Department St Vincent's University Hospital


Medical Oncology Department St Vincent's University Hospital


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings